

**ASX Announcement | 10 October 2023
Vioneering Technologies (ASX:VTI)**

Vioneering Announces Positive Interim 1-Year Data for their NaturalVue® Multifocal 1 Day Contact Lens from the PROTECT Multi-center, Randomized, Double-Masked Clinical Trial for Myopia Progression Control

Highlights:

- PROTECT multi-center, randomized, double-masked, clinical trial (RCT) 1-year patient follow-up clinical data corroborates the safety and efficacy of NaturalVue® Multifocal 1 Day Contact Lenses as a treatment for myopia progression control.
- The PROTECT study's design and execution reflect the highest scientific standards for myopia progression control in pediatric patients.
- The treatment effect* was 0.41D (Diopters), or 69% for refractive error versus the control group.
- For axial length, the treatment effect* was 0.17 mm, or 59%, versus the control group.
- The interim 1-year treatment effects of the NaturalVue Multifocal 1 Day contact lenses are observed to be consistent with those of the only treatment approved by the U.S. Food and Drug Administration (FDA) for myopia progression control.
- This interim 1-year data corroborates the NaturalVue Multifocal 1 Day real-world data analyses.

Vioneering Technologies, Inc. (ASX:VTI) ('Vioneering,' 'VTI' or 'the Company'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, today announced the interim 1-year results from its multi-center, randomized, double-masked, clinical trial known as '**PROTECT**' (**PRO**gressive Myopia **T**reatment **E**valuation for NaturalVue Multifocal **C**ontact Lens **T**rial). The study objective is to demonstrate safety and quantify the effectiveness of its NaturalVue Multifocal 1 Day Contact Lenses for myopia progression control in children.

This multicentered clinical trial has participating investigators in Canada, the United States, Hong Kong, and Singapore. PROTECT is a 3-year study with interim analyses stipulated after the 1-year and 2-year subject follow-ups. One year data from studies of similar design to PROTECT have been predictive of the 3-year results. The final results of the study and any regulatory uses thereof will be based on the analysis of the complete 3-year data set.

The preliminary 1-year results demonstrate the safety and efficacy of NaturalVue Multifocal 1 Day Contact Lenses in slowing myopia progression, providing an important data point for eye care practitioners. Based on a preliminary analysis of the 1-year follow-up from 93% of the enrolled subjects in the PROTECT Clinical Trial*, the treatment effect with NaturalVue Multifocal 1 Day Contact Lenses was 0.41D, or 69% for refractive error, versus the control group. For axial length, the treatment effect was 0.17 mm, or 59%, versus the control group. Combined with the 6-year data previously published in Clinical Ophthalmology in 2022 and the analyses from two other independent

studies released in September 2023, this preliminary one-year data confirms that NaturalVue Multifocal effectively manages eye growth and refractive error change among progressing myopic children. To date, only six study subjects have voluntarily discontinued their participation, reflecting a low drop-out rate of 4%. The Company and the contract research organization conducting the study will continue to review and analyze the interim 1-year data set and plan to share additional details in January 2024.

VTI's Chief Medical Officer, Dr. Ashley Tuan, commented:

"It's exciting to see that the preliminary 1-year data validates our expectations of the safety and effectiveness of NaturalVue Multifocal Contact Lenses for pediatric patients. NaturalVue Multifocal 1 Day also provides clear vision for myopia correction and effectively slows myopia. The interim 1-year treatment effects are consistent with those of the only treatment approved by the FDA for myopia progression control, which we view as a positive result. We look forward to sharing more data from the study in the future."

Chief Executive Officer and Executive Director of VTI, Dr. Juan Carlos Aragón, added:

"Pediatric myopia is one of the most pressing concerns in optometry today, reaching epidemic proportions. VTI has been a pioneer in correcting myopia and protecting children with our innovative and easy-to-fit lens design. That's why we're excited to announce the 1-year interim results of our PROTECT Clinical Trial (RCT) that demonstrates the effectiveness of NaturalVue Multifocal 1 Day for myopia management in children."

Dr. Aragón further commented:

"This data release signals the beginning of a new chapter for VTI as we secure our place on the global map as a positive intervention option in myopia management. The new interim results are outstanding and may support imminent partnering opportunities and commercial growth in key markets throughout Asia and Europe."

VTI expects to release longer-term 2- and 3-year data when available.

*Modified PP (Per Protocol) analysis including children between ages 8 and <13 with refractive error between -0.75 and -4.00 D versus age-matched controls wearing spherical lenses.

Ends

This release was authorized by the CEO, Dr. Juan Carlos Aragón.

For more information, please contact:

<i>Company</i>	<i>Investor and media relations</i>
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres H^CK Tel: +61 423 139 163 Email: haley@hck.digital

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's

flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtvision.com or call +1 844-884-5367, ext. 104.

Foreign ownership restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX84